Form 8-K - Current report:
SEC Accession No. 0002023658-25-000094
Filing Date
2025-08-12
Accepted
2025-08-12 07:41:43
Documents
14
Period of Report
2025-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bcax-20250812.htm   iXBRL 8-K 26505
2 EX-99.1 pressreleaseq22025.htm EX-99.1 88653
6 bicaralogoa.jpg GRAPHIC 6820
  Complete submission text file 0002023658-25-000094.txt   257660

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20250812.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20250812_lab.xml EX-101.LAB 23435
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20250812_pre.xml EX-101.PRE 13579
16 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20250812_htm.xml XML 2910
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42271 | Film No.: 251204057
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)